Current status of antiretroviral therapy.
At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.
Temesgen
Zelalem
Z
Mayo Clinic and Foundation, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA. temesgen.zelalem@mayo.edu
Warnke
David
D
Kasten
Mary J
MJ
D023241:Antiretroviral Therapy, Highly Active / Q000639:trends; D019049:Developed Countries; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D006678:HIV / Q000187:drug effects / Q000201:enzymology / Q000502:physiology; D023581:HIV Fusion Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006297:Health Services Accessibility; D006801:Humans; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States; D014483:United States Dept. of Health and Human Services; D014779:Virus Replication; D014944:World Health Organization
D015507:Drugs, Investigational; D023581:HIV Fusion Inhibitors; D019428:HIV Integrase Inhibitors; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors